Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase I/II results support further development of Leuvectin

Oct. 8, 1999

No Comments

NCI supports clinical development of StressGen's lead product

Oct. 7, 1999

No Comments

York Medical to commence phase I/II trial of head and neck cancer therapy

Sep. 30, 1999

No Comments

ImmunoGen exercises put option

Sep. 30, 1999

No Comments

StressGen completes phase I trial of HspE7

Sep. 28, 1999

No Comments

TriAb prolongs disease progression in breast cancer patients

Sep. 27, 1999

No Comments

GM-CSF and MDX-H210 assessed in pilot trial in cancer patients

Sep. 24, 1999

No Comments

FDA accepts IND for ImmunoGen's tumor-activated prodrug

Sep. 23, 1999

No Comments

Kyowa Hakko begins clinical testing of MAb as melanoma Rx

Sep. 21, 1999

No Comments

Genzyme Molecular Oncology reports preclinical results, collaboration for aaATIII

Sep. 21, 1999

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Immuno-oncology
RSS

Phase I/II results support further development of Leuvectin

NCI supports clinical development of StressGen's lead product

York Medical to commence phase I/II trial of head and neck cancer therapy

ImmunoGen exercises put option

StressGen completes phase I trial of HspE7

TriAb prolongs disease progression in breast cancer patients

GM-CSF and MDX-H210 assessed in pilot trial in cancer patients

FDA accepts IND for ImmunoGen's tumor-activated prodrug

Kyowa Hakko begins clinical testing of MAb as melanoma Rx

Genzyme Molecular Oncology reports preclinical results, collaboration for aaATIII

Today's news in brief

Today's news in brief

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space

GLP-1 receptor agonists continue their global victory tour

AI drives financings, approvals for APAC med-tech in 2024

Immuno-oncology RSS

Immuno-oncology
RSS